GlassScriptPhysician profile
Maryam Elmi
NPI 1144715384
$12,101.10
in general payments reported to CMS, 2019-2025
33 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $246 · 2021: $733 · 2022: $9,626 · 2023: $157 · 2024: $510 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,965.53 | 2021-2022 | |
| Stryker Corporation | $2,148.69 | 2020-2024 | Molli |
| Molli Surgical (US) INC | $323.17 | 2023-2024 | |
| Bard Peripheral Vascular, INC. | $192.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $187.48 | 2023-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $145.60 | 2020-2024 | |
| Dexcom, INC. | $121.78 | 2025 | Dexcom G6 Transmitter |
| Endomagnetics LTD | $105.58 | 2021 | |
| Merit Medical Systems INC | $88.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.39 | 2024-2025 | |
| Incyte Corporation | $65.50 | 2025 | Jakafi, Monjuvi, Zynyz |
| Genmab U.S., INC. | $56.63 | 2024-2025 | Epkinly |
| Tela Bio, INC. | $55.62 | 2024 | Ovitex 2s |
| Merck Sharp & Dohme LLC | $48.53 | 2024-2025 | Keytruda, Lynparza |
| Iovance Biotherapeutics, INC. | $46.71 | 2024-2025 | Amtagvi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $45.31 | 2025 | Columvi, Venclexta |
| Emd Serono, INC. | $44.74 | 2025 | |
| Lilly USA, LLC | $42.04 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $39.88 | 2025 | |
| Eisai INC. | $39.68 | 2025 | |
| Coherus Oncology, INC. | $30.22 | 2025 | Loqtorzi |
| Takeda Pharmaceuticals U.S.A., INC. | $25.49 | 2025 | Alunbrig |
| Legend Biotech USA INC. | $24.98 | 2025 | Carvykti |
| Sun Pharmaceutical Industries INC. | $21.61 | 2025 | |
| Taiho Oncology, INC. | $20.59 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.36 | 2025 | Danziten |
| Alexion Pharmaceuticals, INC. | $19.22 | 2025 | Ultomiris |
| Geron Corporation | $18.28 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $17.14 | 2025 | Onivyde |
| Baxter Healthcare | $16.87 | 2025 | Perclot |
| Regeneron Healthcare Solutions, INC. | $16.04 | 2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $14.09 | 2024 | |
| Pfizer INC. | $14.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Elmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.